GlassScriptPhysician profile
Shruti Sharma
NPI 1609230028
$3,969.14
in general payments reported to CMS, 2019-2025
35 companies · $574 in 2025
The $574 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $145 · 2021: $377 · 2022: $836 · 2023: $941 · 2024: $1,096 · 2025: $574.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,548 · Education: $62.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,548.27 |
| Education | $62.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $354.19 | 2022-2023 | Opdivo, Opdualag |
| Amgen INC. | $294.85 | 2022-2024 | Vectibix, Lumakras |
| Astrazeneca Pharmaceuticals LP | $264.71 | 2021-2023 | Tagrisso |
| Janssen Biotech, INC. | $246.85 | 2024-2025 | Erleada, Akeega, Carvykti |
| Tempus Ai, INC | $193.91 | 2024 | |
| Seagen INC. | $185.22 | 2021-2022 | |
| Myriad Genetic Laboratories, INC. | $176.44 | 2024 | Myrisk |
| Caris Mpi, INC. | $144.05 | 2025 | Mi Cancer Seek |
| Incyte Corporation | $138.35 | 2022 | |
| Karyopharm Therapeutics INC. | $135.26 | 2023-2024 | Xpovio |
| Gilead Sciences, INC. | $133.58 | 2025 | Trodelvy |
| Genmab U.S., INC. | $124.99 | 2024 | Epkinly |
| Bayer Healthcare Pharmaceuticals INC. | $124.99 | 2024 | |
| Novocure INC. | $124.46 | 2023 | Optune Lua (Novottf-200t) |
| Regeneron Healthcare Solutions, INC. | $124.27 | 2025 | Libtayo |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $111.51 | 2023 | Tavalisse, Rezlidhia |
| Intuitive Surgical, INC. | $107.88 | 2024 | |
| Merck Sharp & Dohme LLC | $100.23 | 2020-2022 | |
| Tela Bio, INC. | $100.00 | 2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Pharmacyclics LLC, An Abbvie Company | $99.99 | 2020 | |
| Beigene USA, INC. | $99.94 | 2022 | |
| Abbvie INC. | $89.80 | 2021-2022 | |
| Genzyme Corporation | $85.65 | 2024 | |
| Adc Therapeutics America, INC. | $84.32 | 2022 | |
| Lilly USA, LLC | $72.93 | 2022 | |
| Astellas Pharma US INC | $64.40 | 2021-2025 | |
| Abbott Laboratories | $45.41 | 2023 | Proclaim |
| Eisai INC. | $30.32 | 2020-2022 | |
| Pfizer INC. | $22.99 | 2023 | |
| Eusa Pharma (US) LLC | $21.82 | 2022 | |
| Jazz Pharmaceuticals INC. | $20.59 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $17.47 | 2022 | |
| Blueprint Medicines Corporation | $14.45 | 2024 | Ayvakit |
| Tersera Therapeutics LLC | $13.32 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shruti Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.